稳心颗粒治疗冠心病并室性早搏的临床观察

Clinical investigation of Wenxinkeli in the treatment of coronary heart disease with ventricular premature beats

目的观察稳心颗粒治疗冠心病并室性早搏的临床疗效。方法将符合诊断标准的130例患者分为治疗组(70例)和对照组(60例)。治疗组给予稳心颗粒每次9g口服,3次/日,疗程14d;对照组给予美托洛尔12.5mg口服,2次/日,疗程14d。治疗后依据临床症状、心电图进行分析。结果室性早搏有效率治疗组为77.14%,对照组为78.33%,无显著性差异(P>0.05);心电图改善治疗组为75.71%,对照组为73.33%,无显著性差异(P>0.05);治疗组血压无明显变化,对照组血压降低,两组比较差异有显著性差异(P<0.05)。结论稳心颗粒治疗冠心病并室性早搏的疗效与美托洛尔相当,但对血压影响小,值得临床推广应用。

Objective To investigate the efficacy of Wenxinkeli for coronary heart disease with ventricular premature beats.Methods 130 patients with ventricular premature beats from coronary heart disease were randomized into two groups.One group（n=70） received Wenxinkeli（9g,po,tid） for 14 days.Another controlled group of patients（n=60） were treated with Metoprolol（12.5mg,po,bid） for 14 days.Clinical syndromes and ECG were monitored and compared.Results There was no significant difference in syndrome controlling（77.14% vs 78.33%） and ECG recovery（75.71% vs 73.33%） between two groups（P0.05）.However,the blood pressure decreased significantly in the controll group while there was no change in Wenxinkeli group（P0.05）.Conclusion Wenxinkeli was effective in controlling coronary heart disease with ventricular premature beats which had no side effect on blood pressure,it could be used in clinical practice widely.